Recipient-Related Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation: A Systematic Review and Meta-Analysis

Yao Liu, Yi Liu, Lili Su, Shu-juan Jiang*

Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

Abstract

Background: Primary graft dysfunction (PGD) is the main cause of early morbidity and mortality after lung transplantation. Previous studies have yielded conflicting results for PGD risk factors. Herein, we carried out a systematic review and meta-analysis of published literature to identify recipient-related clinical risk factors associated with PGD development.

Method: A systematic search of electronic databases (PubMed, Embase, Web of Science, Cochrane CENTRAL, and Scopus) for studies published from 1970 to 2013 was performed. Cohort, case-control, or cross-sectional studies that examined recipient-related risk factors of PGD were included. The odds ratios (ORs) or mean differences (MDs) were calculated using random-effects models.

Result: Thirteen studies involving 10042 recipients met final inclusion criteria. From the pooled analyses, female gender (OR 1.38, 95% CI 1.09 to 1.75), African American (OR 1.82, 95% CI 1.36 to 2.45), idiopathic pulmonary fibrosis (IPF) (OR 1.78, 95% CI 1.49 to 2.13), sarcoidosis (OR 4.25, 95% CI 1.09 to 16.52), primary pulmonary hypertension (PPH) (OR 3.73, 95% CI 2.16 to 6.46), elevated BMI (BMI $\geq$ 25 kg/m$^2$) (OR 1.83, 95% CI 1.26 to 2.64), and use of cardiopulmonary bypass (CPB) (OR 2.29, 95% CI 1.43 to 3.65) were significantly associated with increased risk of PGD. Age, cystic fibrosis, secondary pulmonary hypertension (SPH), intra-operative inhaled nitric oxide (NO), or lung transplant type (single or bilateral) were not significantly associated with PGD development (all $P>0.05$). Moreover, a nearly 4 fold increased risk of short-term mortality was observed in patients with PGD (OR 3.95, 95% CI 2.80 to 5.57).

Conclusions: Our analysis identified several recipient related risk factors for development of PGD. The identification of higher-risk recipients and further research into the underlying mechanisms may lead to selective therapies aimed at reducing this reperfusion injury.

Introduction

Although lung transplantation has become an increasingly common procedure in recent years, it has consistently lagged behind other organs in survival rates [1], and early postoperative allograft dysfunction remains a significant cause of post-transplantation morbidity and mortality [2]. Primary graft dysfunction (PGD) is a severe form of acute lung injury induced by ischemia-reperfusion injury that occurs in approximately 10-25% of lung graft recipients [2,3]. Reported 30-day mortality rates of patients with severe PGD are nearly 8 times as high as those for patients without PGD [4]. PGD leads to increased duration of mechanical ventilation and intensive care unit stay, poor functional outcomes, and increase rates of perioperative complications [5].

A number of previous studies have been designed to identify the clinical risk factors associated with PGD [6–23]. This field is of great clinical interest, since better understanding those transplant recipients most at risk might revolve around a concept of earlier detection for targeted therapy and aggressive support. In this regard, a number of clinical risk factors have been identified, including both organ donor and recipient characteristics. Donor characteristics previously identified include female gender, African American race, heavy smokers, older (>45 yr) or younger (<21 yr) donor age, and closed head injury as a cause of death [9,10,18,19,20]. Recipient characteristics previously linked to PGD include a diagnosis of primary pulmonary hypertension (PPH) [6,10,13,19], and elevated pulmonary artery pressures (PAP) [6,19]. In spite of this, there are several recipient-related risk factors that have been inconsistently reported in the literature.

Considering a single study may lack the power of providing a reliable conclusion, we carried out a rigorous systematic review and meta-analysis of published literature to gain more precise and quantitative estimates of recipient-related risk factors associated with development of PGD.
Methods

This meta-analysis followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [24].

Search Strategy

Two reviewers (YL and SJJ) systematically searched PubMed, Embase, ISI Web of Science, Cochrane CENTRAL, and Scopus for articles published until October 2013. The following keywords were used in searching: “primary graft dysfunction” or “primary graft failure” or “ischemia-reperfusion injury” or “acute lung injury” or “early graft failure”, combined with “lung transplantation”. Language restrictions were not applied. From the title, abstract or descriptors, the literature search was reviewed independently to identify potentially relevant trials for full review. The “related articles” function was used to broaden the search. In addition, a manual review of references from primary or review articles was performed to identify any additional relevant studies.

Study selection

Cohort, case-control, and cross-sectional studies were included if they investigated which recipient-related factors directly influencing the development of PGD after lung transplantation. The potential variables assessed could be recipient demographics, co-morbidities, laboratory test, operative data, and postoperative complications. We did not address molecular or genetic markers as these require access to laboratory resources and genetic expertise. After obtaining full reports of candidate studies, the same reviewers independently assessed eligibility. Differences in data between the two reviewers were resolved by reviewing corresponding articles, and the final set was agreed on by consensus. When multiple articles for a single study had been published, we used the latest publication and supplemented it, if necessary, with data from the earlier publications. Attempts were also made to contact investigators for unpublished data.

Data Extraction

Two investigators (YL and SJJ) independently summarized the studies meeting the inclusion criteria, and performed data extraction using a standard data sheet [25]. Disagreement was
Table 1. Characteristics of Selected Studies.

| Author           | Date of study (Year) | Country       | Study Design                          | No. of Subjects (M/F) | Mean age, % | Definition of PGD                                                                 | Quality Assessment |
|------------------|----------------------|---------------|---------------------------------------|------------------------|-------------|----------------------------------------------------------------------------------|-------------------|
| King et al.      | 2000                 | USA           | Retrospective, single-center chart review | 100(NA)                | 49          | Patients with a chest x-ray film (CXR) score of ≤6 and a PaO2/FiO2 gradient of less than 200 mm Hg | Fair              |
| Thabut et al.    | 2002                 | France        | Retrospective multicenter cohort study | 257 (169/88)           | 48          | The presence of reperfusion pulmonary edema with or without early hemodynamic failure. | Fair              |
| Christie et al.  | 2003                 | USA           | Retrospective single-center cohort study | 252(123/129)           | 49          | The presence of a diffuse alveolar infiltrate and a PaO2/FiO2 gradient of less than 200 mm Hg | Good              |
| Whitson et al.   | 2006                 | USA           | Retrospective, single-center chart review | 402 (185/217)          | 50          | ISHLT PGD Grading System                                                          | Fair              |
| Burton et al.    | 2007                 | Denmark       | Retrospective                          | 180 (82/98)            | 56          | The presence of a unilateral diffuse radiological infiltrate of the lung allograft. | Fair              |
| Krenn et al.     | 2007                 | Austria       | Prospective single-center cohort study | 150 (76/74)            | 38          | ISHLT PGD Grading System                                                          | Good              |
| Kuntz et al.     | 2009                 | USA           | Secondary analysis of multicenter registry (UNOS/ISHLT) | 6984 (4315/2669)      | —           | A PaO2/FiO2 ratio less than 200, with evidence of radiographic infiltrates, and absence of secondary causes of allograft dysfunction. | Good              |
| Felten et al.    | 2011                 | France        | Retrospective, multicenter cohort study | 122 (63/59)            | 25          | ISHLT PGD Grading System                                                          | Good              |
| Fang et al.      | 2011                 | USA           | Prospective multicenter cohort study   | 126 (60/66)            | 56          | ISHLT PGD Grading System                                                          | Good              |
| Allen et al.     | 2012                 | USA           | Prospective, single-center cohort study | 28 (12/16)             | 51          | ISHLT PGD Grading System                                                          | Fair              |
| Shah et al.      | 2006–2008            | USA           | Prospective multicenter cohort study   | 108 (56/52)            | 37          | ISHLT PGD Grading System                                                          | Good              |
| Samano et al.    | 2003–2010            | Brazil        | Retrospective, single-center chart review | 78 (46/32)            | 44          | ISHLT PGD Grading System                                                          | Fair              |
| Diamond et al.   | 2013                 | USA           | Prospective, multicenter cohort study (LTOG) | 1255 (211/1044)       | 35          | ISHLT PGD Grading System                                                          | Good              |

M, male; F, female; PGD, primary graft dysfunction; ISHLT, International Society for Heart and Lung Transplantation.

doi:10.1371/journal.pone.0092773.t001
resolved by consensus or by a third party. For each study, the following data were extracted: first author’s last name, publication year, study date, country, study design, sample size, patient characteristics (age and gender) and definition of PGD. Initially, we scrutinized in detail the literature about PGD after lung transplantation to identify all possible risk factors. The initial search yielded 18 possible risk factors. Following review by an expert panel (YL, LLS and SJJ), 10 factors that were considered to be easily measured in routine clinical practice and had been analyzed in at least 2 studies were selected for the full systematic review. These factors assessed including age, gender, race, pulmonary diagnosis, PAP, type of transplant (single lung transplant (SLT) vs bilateral lung transplant (BLT)), body mass index (BMI), cardiopulmonary bypass (CPB), intra-operative inhaled nitric oxide (NO), and blood products transfusion.

Study Quality Assessment

The Newcastle-Ottawa Scale was used to assess the quality of observational studies based on the following nine questions: (1) representativeness of the exposed cohort; (2) selection of the non-exposed cohort; (3) ascertainment of exposure; (4) demonstration that the outcome was not present at outset of study; (5) comparability; (6) assessment of outcome; (7) length of follow-up sufficient; (8) adequacy of participant follow-up; (9) total stars [26]. Maximum score on this scale is a total of 9. “Good” was defined as a total score of 7 to 9; “fair,” a total score of 4–6; and “poor,” defined as a total score of <4.

Statistical analyses

Our meta-analysis and statistical analyses were performed with Revman software (version 5.2; Cochrane Collaboration, Oxford, United Kingdom) and Stata software (version 11.0; Stata Corporation, College Station, TX, USA). The odds ratios (ORs)

**Table 2.** The recipient-related risk factors examined in the original articles.

| Author     | Age | Gender | Race | Pulmonary Diagnosis | PAP | BLT vs SLT | BMI | CPB | Inhaled NO | Blood products transfusion | Mortality |
|------------|-----|--------|------|---------------------|-----|------------|-----|-----|------------|----------------------------|-----------|
| King et al |     |        |      |                     |     |            |     |     |            |                            |           |
| Thabut et al |   |        |      |                     |     |            |     |     |            |                            |           |
| Christie et al | |        |      |                     |     |            |     |     |            |                            |           |
| Whitson et al |   |        |      |                     |     |            |     |     |            |                            |           |
| Burton et al |   |        |      |                     |     |            |     |     |            |                            |           |
| Krenn et al |     |        |      |                     |     |            |     |     |            |                            |           |
| Kuntz et al |     |        |      |                     |     |            |     |     |            |                            |           |
| Felten et al |     |        |      |                     |     |            |     |     |            |                            |           |
| Fang et al  |     |        |      |                     |     |            |     |     |            |                            |           |
| Allen et al |     |        |      |                     |     |            |     |     |            |                            |           |
| Shah et al |     |        |      |                     |     |            |     |     |            |                            |           |
| Samano et al |    |        |      |                     |     |            |     |     |            |                            |           |
| Diamond et al | |        |      |                     |     |            |     |     |            |                            |           |

PAP, pulmonary artery pressure; BLT, bilateral lung transplant; SLT, single lung transplant; BMI, body mass index; CPB, cardiopulmonary bypass; NO, nitric oxide.

doi:10.1371/journal.pone.0092773.t002

**Figure 2.** The influence of recipient gender on PGD.

doi:10.1371/journal.pone.0092773.g002
and 95% confidence intervals (CIs) were calculated to estimate the association between binary factors and development of PGD. When mean values and SDs for a certain risk factor were provided, we calculated the mean differences (MDs) between patients with and without PGD. The statistical estimates of effect were derived using a random-effects (DerSimonian and Laird) model, which assumes that the true underlying effect varies among included studies, because of the different characteristics of study population, transplantation procedure, and the PGD definitions that were involved in the original trials.

The definitions of PGD may be a potential source of heterogeneity. In order to analyze the heterogeneity associated with different definitions, we performed subgroup analyses by comparing summary results obtained from subsets of studies grouped by “the International Society for Heart and Lung Transplantation (ISHLT) PGD Grading System [28]” or other definitions. Statistical heterogeneity of treatment effects between studies was formally tested with Cochran’s $\chi^2$ statistics and with significance set at $P = 0.10$. The $I^2$ statistic was used to quantify heterogeneity. Using accepted guidelines [27], an $I^2$ of 0% to 40% was considered to exclude heterogeneity, an $I^2$ of 30% to 60% to represent moderate heterogeneity, an $I^2$ of 50% to 90% to represent substantial heterogeneity, and an $I^2$ of 75% to 100% to represent considerable heterogeneity. Publication bias was assessed with funnel plots and the Begg’s test.

Results

Literature search and study characteristics

The method used to select studies is shown in Figure 1. A total of 331 potentially eligible articles were initially identified, and 289 articles were excluded as they were not relevant to the purpose of the current meta-analysis. Therefore, 42 potentially relevant articles were selected for detailed evaluation. From the overall pool of full-text articles, 29 articles were excluded because they did not provide PGD data according to the risk factors we evaluated (n = 16), reported the risk factors in an unusable format (n = 3), did not make any objective diagnosis of PGD (n = 4), or were duplicate studies (same cohort of patients with different endpoints measured) (n = 6). Thus, 13 studies were included in the meta-analysis with a total of 10042 patients [7–19]. Additional data were requested from the authors of three studies but didn’t receive any reply.

Baseline characteristics of the studies included are shown in Table 1. The 13 included studies consisted of 5 prospective cohort studies [12,15–17,19], 7 retrospective analyses of cohort data or chart review [7–11,14,18], and 1 secondary analysis of multicenter registry [13]. Eight of the 13 studies involved American subjects [7,9,10,13,15–17,19], and the populations of the remaining five studies came from France [8,14], Denmark [11], Austria [12], and Brazil [18]. The studies varied in size from 28 to 6984 subjects, and the average age of the patients ranged from 25 to 56 years.

There were some variations in the definition of PGD. The ISHLT PGD grading schema was used in the majority of the studies. The other 5 studies also defined PGD based on the presence of infiltrates in the lung allograft on chest radiograph and/or the PaO2/FiO2 ratio [7–9,11,13]. PGD, as defined in the original articles, was present in 16.4% of the lung transplant patients. All studies were of high methodological quality (good or fair) as assessed by the Newcastle-Ottawa Scale [26] (Table 1). The risk factors examined in the 13 included studies are summarized in Table 2.

Outcomes and synthesis of results

Age. Ten studies investigated the influence of recipient age on the occurrence of PGD [7–9,11,12,14–18], including 434 patients with PGD and 969 controls. Findings from this analysis suggested no significant difference in mean age between patients with or without PGD (MD -0.75 y, 95% CI -2.12 to 0.63 y, $P = 0.29$). Statistical heterogeneity among the studies was significant ($I^2 = 61\%$, $P = 0.006$).

Gender. Twelve studies investigated the influence of recipient gender on the occurrence of PGD [8–19]. These studies included 1506 patients with PGD and 8430 controls. The proportion of
female recipients was 55.3% in patients with PGD compared with 49.0% in patients without. Analysis suggested female recipients had an increased risk of PGD (OR 1.38, 95% CI 1.09 to 1.75, \(P = 0.008\)) (Figure 2).

**Race.** Five studies reported the influence of recipient race [9,13,15,17,19]. PGD was found in 11.4% of patients with white race, 19.1% of African American patients, and 18.7% of Hispanic patients. White race was used as the reference group given the lowest incidence of PGD. Analysis of these studies showed compared with white race, African American was associated with a significantly increased risk of PGD (OR 1.82, 95% CI 1.36 to 2.45, \(P = 0.001\)) [7–10,12,13,16,17,19] (Figure 3); while Hispanic race did not appear to affect the risk of PGD (OR 1.04, 95% CI 0.32 to 3.42, \(P = 0.91\)) [8–10,12,13,16,17,19] (Figure 3).

**Pulmonary Diagnosis.** The effect of recipient pulmonary diagnosis on PGD development was evaluated in 10 studies [7–13,16,17,19]. The incidence of PGD was 11.6% in patients with chronic obstructive pulmonary disease (COPD), 18.0% in patients with idiopathic pulmonary fibrosis (IPF), 50% in sarcoidosis and 12.4% in cystic fibrosis. For patients with pulmonary hypertension, PGD was observed in 30.3% of patients with PPH and 29.3% of secondary pulmonary hypertension (SPH).

Using COPD as the reference group (with the lowest incidence of PGD), IPF (OR 1.78, 95% CI 1.49 to 2.13, \(P < 0.0001\)) [7–13,16,17,19] and sarcoidosis (OR 4.25, 95% CI 1.09 to 16.32, \(P = 0.04\)) [7,16–17] were both associated with increased risk of PGD; while cystic fibrosis was non-significantly associated with PGD development (OR 1.28, 95% CI 0.89 to 1.84, \(P = 0.18\)) [8–10,12,13,16,17,19] (Figure 4). PPH was also significantly associated with PGD, with a 3.73-fold increased risk of PGD was observed (OR 3.73, 95%CI 2.16 to 6.46, \(P = 0.001\)) [7–10,12,13,16,17,19]; while unlike PPH, SPH did not confer an significantly increased risk of PGD (OR 2.23, 95%CI 0.65 to 7.69, \(P = 0.20\)) [10,13] (Figure 5).

**PAP.** There were 7 studies compared the mean PAP between patients with and without PGD (325 PGD patients and 1093 controls) [7,9,12,15–17,19]. Findings from the meta-analysis showed a significant higher PAP was observed in the PGD patients as compared with the controls (MD 6.00 mmHg, 95% CI 3.91 to 8.09 mmHg, \(P < 0.0001\)). Statistical heterogeneity was observed among the studies (\(I^2 = 77%\), \(P = 0.0003\)) (Figure 6).

**BLT vs. SLT.** Eleven studies evaluated the impact of BLT vs. SLT on PGD development, including 4554 patients undergoing
BLT and 5190 patients undergoing SLT [7–10,12,13,15–19]. The pooled analysis showed the incidence of PGD was 14.5% in BLT recipients, compared to 13.8% in SLT recipients. Findings from the meta-analysis showed an insignificant association between the transplant type (SLT or BLT) and PGD (OR 1.10, 95% CI 0.97 to 1.24, P = 0.14). No statistically significant heterogeneity was observed between studies (I2 = 0%, P = 0.65).

**BMI.** Two studies evaluated the effect of BMI (as a continuous variable) on PGD [11,14], including 155 patients with PGD and 147 controls. The pooled analysis of the 2 studies showed patients with PGD had a higher mean BMI level than controls (MD 1.20 kg/m², 95% CI 0.13 to 2.27 kg/m², P = 0.03). Other 2 studies investigated the impact of elevated BMI (BMI≥25 kg/m²) on PGD development [13,19]. The incidence of PGD was 15.2% in the 3105 patients with elevated BMI, compared to 9.4% in the 5091 patients with normal BMI. Analysis of these studies showed a significant association between elevated BMI level and PGD (OR 1.83, 95% CI 1.26 to 2.64, P = 0.001).

**CPB.** Eleven studies evaluated the effect of CPB for PGD [7,8,10–12,14–19]. PGD was found in 263 of 813 patients (32.3%) use of CPB compared to 490 of 1984 patients (24.7%) without CPB. The pooled analysis of these studies showed a 2.29-fold increased risk of PGD was present for patients requiring CPB (OR 2.29, 95% CI 1.43 to 3.65, P = 0.0005), with statistical heterogeneity among the studies (I2 = 69%, P = 0.004).

**Inhaled NO.** Four studies investigated the influence of intra-operative use of inhaled NO on the occurrence of PGD [9,14–16]. The incidence of PGD was 23.4% (50 of 214 patients) and 18.8% (59 of 314 patients) in patients with and without use of inhaled NO, respectively. Findings from this analysis suggested there was no significant association between intra-operative inhaled NO use and development of PGD (OR 1.09, 95% CI 0.68 to 1.74).
Discussion

Despite the significant morbidity and mortality in patients with PGD after lung transplantation, the recipient related risk factors contributing to this devastating syndrome remain controversial. Our meta-analysis comprehensively reviewed 13 studies involving 10042 lung transplantation recipients which addressed the clinical risk factors for PGD. The results showed recipient female gender, African American race, preoperative diagnosis of IPF, sarcoidosis, or PPH, elevated mean PAP and BMI, use of CPB and blood products transfusion were significantly and consistently associated with development of PGD. All of these factors are likely to be measured and monitored in the primary care setting. To the best of our knowledge, this is the first systematic review on this topic.

Among baseline variables, we have demonstrated that female gender and African-American race had increased risk of PGD, which have not been validated in previous studies. Female gender has been associated with a higher risk of development of acute respiratory distress syndrome (ARDS) in the Ibuprofen in Sepsis Study Group [29], as well as in a cohort study of trauma patients [30]. Similarly, donor female gender was also shown to have an independent impact on PGD [9]. Possible mechanisms for these findings are unclear. Some theories for the differential outcome based on gender differences have been advocated, including immunity and tolerance theories [31] and the influence of gender hormones [32]. However, as of now few data have been published that evaluate the effect of gender on graft function and survival. Similarly, mechanisms for the observed worse outcome of African-American race remain speculative, but may reflect differences in vascular endothelium (such as expression of angiotensin-converting enzyme) [33,34], which could potentially predispose African Americans to more severe ischemia reperfusion injury.

Elevated BMI was another risk factor for PGD in our meta-analysis. Prior studies have identified obesity as a risk factor for early mortality and increased intensive care unit stay after lung transplant [35,36]. Technical difficulties of performing a lung transplant operation in obese recipients may increase risk of PGD. Other possible explanations may be obesity affects the milieu of cytokines produced by adipose tissue during ischemia-reperfusion, such as leptin [37], which has been shown to be increased in patients with acute lung injury and play a role in the development of acute lung injury in animal model [38]. In the study by Lederer et al, higher plasma leptin levels were associated with PGD after lung transplantation [39]. In addition, modulation of lung inflammation by other adipokines, such as resistin, adiponectin, which produced by macrophages recruited to hypertrophic and hypoxic adipose tissue, could also be responsible [39–41]. Future studies of adipokines in lung tissue or bronchoalveolar lavage fluid and examination of their roles in the development of PGD should be pursued.
In nearly all previous studies, diagnosis of PPH was the most significant risk factor for PGD [6,10,13,19], and our findings further support this, showing both PPH and elevated mPAP were strongly associated with PGD after lung transplant. Possible explanations are not fully understood. In PPH, right ventricular dysfunction is universally present, and the hypertrophied, failing right ventricle is acutely afterload reduced at transplantation, resulting in increased shear stress on the formerly hypoxic pulmonary vascular endothelium. Shear stress leads to capillary leak and worse graft function [42,43]. Christie et al showed diagnosis of PPH was even more strongly associated with an increased risk of PGD after adjustment for recipient PAP (adjusted RR = 9.24, \( P = 0.009 \)) [9]. This implies it is the disease state of PPH that increases the risk, rather than just the presence or severity of pulmonary hypertension. Unlike PPH, our study suggested SPH did not confer an increased risk of PGD. In prior studies, the association between SPH and PGD was controversial and the conclusions were inconsistent [10,13,15,18]. Fang et al demonstrated SPH in patients with IPF was independently associated with the development of PGD [15]. While for patients with CF, based on data from the ISHLT registry, no significant difference was observed in PGD incidence for patients with and without pulmonary hypertension [6]. These findings suggested that the association between pulmonary hypertension and PGD might depend on the underlying diagnoses to some extent. For studies included in this meta-analysis, SPH has been all-inclusive, regardless of cause [10,13,18]. Therefore, for further discussion, it is better to focus on the primary disease of SPH.

IPF was also identified as a risk factor with intermediate risk of PGD in our analysis. Previous observational studies reported patients undergoing transplantation for IPF had somewhat worse survival than for other indications, when matched on multiple recipient-related risk factors [42,43]. Table 3: Subgroup analysis according to the definitions for PGD.

| Subgroup | No. of studies | Test for association | Test for subgroup difference |
|----------|----------------|----------------------|----------------------------|
|          | Age            |                      |                            |
|          |                | OR (95% CI)          | \( p \)                    |
| ISHLT    | 5              | \(-1.33 (-5.09 to 2.43)\) | 0.49                       |
| Other definitions | 5     | \(-0.58 (-2.17 to 1.10)\) | 0.48                       |
|          | Female         |                      |                            |
|          |                |                      |                            |
| ISHLT    | 8              | \(1.21 (0.82 to 1.77)\) | 0.33                       |
| Other definitions | 4     | \(1.50 (1.23 to 1.83)\) | <0.001                     |
|          | Race           |                      |                            |
|          |                |                      |                            |
| African-American | 3    | \(2.28 (1.55 to 3.36)\) | <0.001                     |
| Other definitions | 3     | \(1.37 (0.68 to 2.74)\) | 0.38                       |
|          | Diagnosis      |                      |                            |
|          |                |                      |                            |
| IPF      | 5              | \(1.88 (1.40 to 2.54)\) | <0.001                     |
| Other definitions | 5     | \(1.65 (1.14 to 2.38)\) | 0.0009                     |
| Cystic fibrosis | 5     | \(1.41 (0.63 to 3.18)\) | 0.41                       |
| Other definitions | 3     | \(1.20 (0.93 to 1.55)\) | 0.16                       |
| PPH      | 5              | \(6.58 (1.04 to 41.59)\) | <0.001                     |
| Other definitions | 3     | \(4.04 (3.12 to 5.24)\) | 0.05                       |
| Mean PAP |                |                      |                            |
|          |                |                      |                            |
| ISHLT    | 4              | \(5.80 (1.65 to 9.94)\) | 0.006                      |
| Other definitions | 3     | \(6.93 (5.69 to 8.17)\) | <0.001                     |
| BLT vs SLT |              |                      |                            |
|          |                |                      |                            |
| ISHLT    | 6              | \(1.06 (0.84 to 1.33)\) | 0.63                       |
| Other definitions | 5     | \(1.11 (0.96 to 1.28)\) | 0.15                       |
| CPB      | 7              | \(2.31 (1.23 to 4.33)\) | 0.009                      |
| Other definitions | 4     | \(2.62 (1.47 to 4.66)\) | 0.001                      |
| Use of inhaled NO |          |                      |                            |
|          |                |                      |                            |
| ISHLT    | 2              | \(1.22 (0.59 to 2.51)\) | 0.60                       |
| Other definitions | 2     | \(1.00 (0.54 to 1.85)\) | 0.99                       |

PGD, primary graft dysfunction; ISHLT, International Society for Heart and Lung Transplantation; IPF, idiopathic pulmonary fibrosis; PPH, primary pulmonary hypertension; PAP, pulmonary artery pressure; BLT, bilateral lung transplant; SLT, single lung transplant; CPB, cardiopulmonary bypass; NO, nitric oxide.

DOI:10.1371/journal.pone.0092773.t003.
variables [44,45]. Possible explanations may be related to the pathogenesis of IPF. IPF carries a progressive course of pulmonary dysfunction that is inhibited, but not eliminated, by transplantation. Vasoactive mediators such as endothelin-1, platelet-derived growth factor, transforming growth factor-β, and fibroblast growth factor have all been implicated in the pathogenesis of IPF, and also contribute to the development of lung injury [46]. Moreover, IPF patients have a restrictive pattern of pulmonary disease with smaller-than-predicted total lung capacity. Shrinking lung volume may have caused irreversible damage to pulmonary mechanics by contracting the chest wall (remodeling). This relative “oversize” donor lung within smaller chest may lead to worse graft function [45,47]. Nevertheless, at this point, reasons for the poor outcomes of IPF after transplantation remain elusive and warrant focused investigation.

The intra-operative use of CPB was another potential contributor to PGD in our meta-analysis. CPB causes a systemic, pro-inflammatory response with activation of cytokines, leukocytes and the complement cascade [48,49]. Patients requiring CPB have been shown to have more radiographic infiltrates, worse immediate graft function, longer intubation, and ultimately, decreased survival [50,51]. However, a notable difficulty in interpreting the data is the overall severity of the patient’s illness or operative difficulty requiring the use of CPB. It is not possible to accurately differentiate planned use of CPB from emergent initiation intraoperatively because of deterioration in patient hemodynamics or oxygenation. As a result, independent of indication for CPB use, the association between PGD and CPB is still debatable. The type of transplant procedure (bilateral vs. single) was not identified as a significant risk factor for PGD in our study. Although the reported incidence of PGD was somewhat higher in BLT recipients, higher pre-transplant PAP and CPB use in BLT recipients likely confounded these results [5,10].

The finding of blood products transfusion as a risk factor for PGD has been shown in recent multicenter studies and our meta-analysis confirmed this tendency [19,52], but the exact relationship between the two processes is not yet clear. Blood products transfusion in-and-of itself is associated with transfusion-related lung injury, which results in an ARDS-like picture similar to that seen with PGD [53]. The transfusion-related lung injury might accentuate any underlying mild ischemia/reperfusion injury, resulting in the onset of clinically significant PGD [53]. Nonetheless, the need for blood products administration has been shown to colinear with other PGD risk factors, including PPH and the use of CPB, and unmeasured operative characteristics may also lead to transfusion requirements [54]. Therefore dissecting the independence of the relationship between blood transfusion and PGD is difficult.

Inhaled NO has been investigated as a potential agent for the prevention of PGD, given its effects on pulmonary vasodilation and capillary integrity. Although our analysis did not support use of inhaled NO to be effective in PGD prevention, it may be beneficial in clinical settings of established PGD. Several reports and case series have shown improved outcomes with inhaled NO administration [55,56]. However, there have also been studies that do not show efficacy in the setting of PGD [57]. Lack of randomized clinical trials showing survival benefit precludes widespread recommendation of inhaled NO for the treatment of PGD. Again, extrapolating from inhaled NO use in studies with ARDS, the beneficial effects of inhaled NO may be real, but also appear to be transient [58].

Limitations of the review

Although we believe that the current meta-analysis provided useful information, some potential limitations should be addressed. Firstly, heterogeneity in our study is substantial and may be attributed to differences in type of patients, study era, operative practice, and definition of PGD. Definition of PGD is a major cause of heterogeneity, and with potential for misclassification bias. As the ISHLT PGD criteria were first published in 2005, studies performed before 2005 did not use standard defining criteria; even for the studies defined PGD based on the ISHLT guidelines, the PGD grades were retrospectively assigned to those patients enrolled before 2005. To clarify the heterogeneity, subgroup analyses were performed by dividing studies according to ISHLT or other definitions, and the results suggested our
findings were not significantly affected by varying definitions. Secondly, our analysis was by necessity restricted to individual risk factors. Therefore, the distinct possibility exists that the strength of association may be weaker with a multi-factorial regression analysis. For instance, the individual effects of CIP, use of blood products, and elevated PAP cannot be delineated since they are often apparent in the same patients. In the present meta-analysis, it was not possible to adjust or stratify for potential confounders, which restricted us from doing more detailed relevant analysis and obtaining more comprehensive results. Finally, given that a proportion of studies included are retrospective, a possibility of residual confounding variables by unmeasured factors cannot be eliminated. This provided associative, not causal, evidence and mandates caution when interpreting these results.

Conclusion

Our systematic review and meta-analysis have identified several recipient-related risk factors for development of PGD, all of which are readily available in clinical settings. The identification of higher-risk recipients has great clinical relevance with respect to individual screening, risk factor modification, selective management aimed at prevention of PGD, and ultimately improves the outcomes of patients undergoing lung transplantation. Further research into the underlying mechanisms responsible for these associations should be advocated.

Supporting Information

Checklist S1 The PRISMA Checklist for this Systematic Reviews and Meta-Analyses.

Author Contributions

Conceived and designed the experiments: Yao Liu Yi Liu LS SJJ. Performed the experiments: Yao Liu Yi Liu SJ. Analyzed the data: Yao Liu LS SJJ. Contributed reagents/materials/analysis tools: Yao Liu Yi Liu SJ. Wrote the paper: Yao Liu SJ.

References

1. Arcasoy SM, Kozloff RM (1999) Lung transplantation. N Engl J Med 340:1081–1091.
2. Christie JD, Van Raemdonck D, de Perrot M, Barr M, Keshavjee S, et al. ISHLT Working Group on Primary Lung Graft Dysfunction (2005) Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods. J Heart Lung Transplant 24:1451–1453.
3. King RG, Binns OA, Rodriguez F, Kanitathan RC, Daniel TM, et al. (2000) Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 69:1681–1695.
4. Christie JD, Kozloff RM, Ahya VN, Tino G, Pochettino A, et al. (2005) The effect of primary graft dysfunction on survival after lung transplantation. J Am Resp Crit Care Med 171:1312–1313.
5. Lee JC, Christie JD, Keshavjee S (2010) Primary graft dysfunction: definition, risk factors, short- and long-term outcomes. Semin Resp Crit Care Med 31:161–71.
6. Barr ML, Kozloff SM, Whelan TP, Gregis R, Bokchek H, et al. (2005) Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 24:1468–1462.
7. King RG, Binns OA, Rodriguez F, Kanitathan RC, Daniel TM, et al. (2000) Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 69:1681–1695.
8. Thabut G, Vinatier I, Stern JB, Leséché G, Loriot P, et al. (2002) Primary graft failure following lung transplantation: predictive factors of mortality. Chest 121:1076–82.
9. Christie JD, Kozloff RM, Pochettino A, Arcasoy SM, Rosengard BR, et al. (2003) Clinical risk factors for primary graft failure following lung transplantation. Chest 124:1229–1241.
10. Whiston RA, Nair DN, Johnson AC, Walker AR, Prekker ME, et al. (2006) Risk factors for primary graft dysfunction after lung transplantation. J Thoracic Cardiovasc Surg 131:73–80.
11. Burton CM, Iversen M, Milman N, Zemtsovski M, Carlsen J, et al. (2007) Outcome of lung transplanted patients with primary graft dysfunction, Eur J Cardiothorac Surg 31:73–82.
12. Krenn K, Klepetko W, Taghavi S, Lang G, Schneider B, et al. (2007) Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant 7:780–6.
13. Kutty CI, Hadjidoulis D, Ahya VN, Kozloff RM, Pochettino A, et al. (2009) Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 23:819–30.
14. Fleros MK, Sinaeur M, Trellauma M, Roze H, Mornex JF, et al. (2012) Factors associated with early graft dysfunction in cystic fibrosis patients receiving primary bilateral lung transplantation. Eur J Cardiothorac Surg 41:686–90.
15. Fang A, Studer S, Kozloff SM, Ahya VN, Lee J, et al. Lung Transplant Outcomes Group (2011) Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 139:782–7.
16. Allen JG, Lee MT, Weiss ES, Arnaoutakis GJ, Shah AS, et al. (2012) Preoperative recipient cytokine levels are associated with early lung allograft dysfunction. Ann Thorac Surg 93:1043–1047.
17. Shah RJ, Diamond JM, Leiderer DJ, Arcasoy SM, Canut EM, et al. (2012) Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. Transplant Res 10:415–42.
18. Samano MN, Fernandez LM, Baranaukas JC, Correia AT, Alfonso JR, et al. (2012) Risk factors and survival impact of primary graft dysfunction after lung transplantation in a single institution. Transplant Proc 44:2462–8.
19. Diamond JM, Lee JC, Kozloff SM, Shah RJ, Localio AR, et al. (2013) Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 187:527–34.
20. de Perrot M, Bemer RS, Darl J, Kelly RF, McGriffin D, et al. (2005) Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 24:1468–1467.
21. Abo R, Griffith BP, Kormos RL, Armitage JM, Gasior TA, et al. (1994) Effect of cardiopulmonary bypass on early graft dysfunction in clinical lung transplantation. Ann Thorac Surg 57:715–22.
22. Shigemura N, Toyoda Y, Bhamma JK, Gries CJ, Crespo M, et al. (2013) Donor smoking history and age in lung transplantation: a revisit. Transplantation 95:515–8.
23. Alvarza A, Moreno P, Illana J, Espinoza D, Baamonde C, et al. (2011) Influence of donor-receptor gender mismatch on graft function and survival following lung transplantation. Interact Cardiovasc Thorac Surg 16:426–35.
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA 283:2008–2012.
25. Moher D, Cook JH, Eastwood S (1999) Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896.
26. Wells G, Shea B, O’Connell D, Guyatt G, Peterson J, et al. (2006) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa Health Research Institute (OHRI).
27. Higgins JPT, Green S, eds (2009) Cochrane handbook for systematic reviews of interventions. Version 5.0.2. New York, NY: Wiley. The Cochrane Collaboration. Available: www.cochrane-handbook.org. Accessed: 2008 June.
28. Christie JD, Carby M, Bag R, Corris P, Hertz M, et al. (2005) Report of the ISHLT working group on primary lung graft dysfunction, part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 24:1454–9.
29. Mangialardi RJ, Martin GS, Bernard GK, Wheeler AP, Christman BW, et al. (2000) Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis: Basprofen in Sepsis Study. Grup Soc Med 28:3137–3145.
30. Hudson LD, Milberg JA, Anardii D, Maundre RJ (1995) Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 151:293–301.
31. Simpson E, Scott D, Chandler P (1997) The male-specific histocompatibility antigen. Ann Rev Immunol 15:39–61.
32. Swearer N, Telepchevich S, Cagnot S, Furtuck P, Hertz M, et al. (2005) Report of the ISHLT working group on primary lung graft dysfunction, part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 24:1454–9.
33. Manguarà RJ, Martin GS, Bernard GK, Wheeler AP, Christman BW, et al. (2000) Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis: Basprofen in Sepsis Study. Grup Soc Med 28:3137–3145.
34. Jones DS, Ambraessi NS, Abernethy DR (1999) Impaired forearm vascular relaxation in black Americans. Clin Pharmacol Ther 65:408–15.
35. Kanasky WF Jr, Anton SD, Rodrigue JR, Perri MG, Szwed T, et al. (2002) Impact of body weight on long-term survival after lung transplantation. Chest 121:401–6.

36. Madill J, Gutierrez C, Grossman J, Allard J, Chan C, et al. (2001) Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 20:288–96.

37. Jain M, Budlinger GS, Lo A, Urich D, Rivera SE, et al. (2011) Leptin promotes fibroproliferative ARDS by inhibiting peroxisome proliferator-activated receptor-γ. Am J Respir Crit Care Med 183:1490–1498.

38. Bellmeyer A, Martino JM, Chandel NS, Scott Budinger GR, Dean DA, et al. (2007) Leptin resistance protects mice from hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 176:875–80.

39. Jain M, Budinger GS, Lo A, Urich D, Rivera SE, et al. (2011) Leptin promotes fibroproliferative ARDS by inhibiting peroxisome proliferator-activated receptor-γ. Am J Respir Crit Care Med 183:1490–1498.

40. Lederer DJ, Kawut SM, Wickersham N, Winterbottom C, Bhorade S, et al. (2011) Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 184:1055–1061.

41. Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, et al. (2009) Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 41:397–406.

42. Pierre AF, DeCampos KN, Liu M, Edwards V, Cutz E, et al. (1996) Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol 271:L1035–L1042.

43. Garat C, Jayr C, Eddahibi S, Laffon M, Meignan M, et al. (1997) Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury. Am J Respir Crit Care Med 155:1957–1964.

44. Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, et al. (2005) Report of the ISHLT working group on primary lung graft dysfunction: Part VI. Treatment. J Heart Lung Transplant 24:1409–1500.